Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 34891224

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2022 Feb 17
First author
Locke FL

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2022 Feb 17;386(7):692-696. doi: 10.1056/NEJMe2118899.
    note
    Source null
    related pmid
    34904797
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Feb;19(2):71. doi: 10.1038/s41571-021-00598-7.
    note
    Source null
    related pmid
    34987189
    relationship
    Comment in
  3. citation
    Cancer Cell. 2022 Feb 14;40(2):131-133. doi: 10.1016/j.ccell.2022.01.013.
    note
    Source null
    related pmid
    35167823
    relationship
    Comment in

Authors and identifiers

  1. name
    Locke FL
    type
    Author
  2. name
    Miklos DB
    type
    Author
  3. name
    Jacobson CA
    type
    Author
  4. name
    Perales MA
    type
    Author
  5. name
    Kersten MJ
    type
    Author
  6. name
    Oluwole OO
    type
    Author
  7. name
    Ghobadi A
    type
    Author
  8. name
    Rapoport AP
    type
    Author
  9. name
    McGuirk J
    type
    Author
  10. name
    Pagel JM
    type
    Author
  11. name
    Muñoz J
    type
    Author
  12. name
    Farooq U
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Locke FL
    type
    Author
  2. name
    Miklos DB
    type
    Author
  3. name
    Jacobson CA
    type
    Author
  4. name
    Perales MA
    type
    Author
  5. name
    Kersten MJ
    type
    Author
  6. name
    Oluwole OO
    type
    Author
  7. name
    Ghobadi A
    type
    Author
  8. name
    Rapoport AP
    type
    Author
  9. name
    McGuirk J
    type
    Author
  10. name
    Pagel JM
    type
    Author
  11. name
    Muñoz J
    type
    Author
  12. name
    Farooq U
    type
    Author
bibliography ids
  1. nci-bib-9b223798afb2cc2a05388b21
book metadata
content sha256
073b3b39314dcff00c23352920fdbd477e946e9f20d8eb16d685d804c4b16983
document type
citation
dois
  1. 10.1056/NEJMoa2116133
electronic publication date
display
2021 Dec 11
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34891224
immutable id
pubmed:34891224@073b3b39314dcff00c23352920fdbd477e946e9f20d8eb16d685d804c4b16983
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
7
name
The New England journal of medicine
nlm unique id
0255562
pages
640-654
volume
386
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2022 Feb 17;386(7):692-696. doi: 10.1056/NEJMe2118899.
    note
    Source null
    related pmid
    34904797
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Feb;19(2):71. doi: 10.1038/s41571-021-00598-7.
    note
    Source null
    related pmid
    34987189
    relationship
    Comment in
  3. citation
    Cancer Cell. 2022 Feb 14;40(2):131-133. doi: 10.1016/j.ccell.2022.01.013.
    note
    Source null
    related pmid
    35167823
    relationship
    Comment in
outcomes validated
false
pmid
34891224
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
73a026a1aba1704fb4125b36aa69905aa1774baa741fded9d027e23146735275
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Feb 17
precision
day
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34891224/
title
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

Preserved source evidence · Independent clinical review pending · Not medical advice